Generic drug maker Mylan Inc. yesterday reported net income for the second quarter of $58.1 million, or 19 cents per share, up from a loss of $16.3 million, or 5 cents per share, a year earlier when it took charges for the acquisition of Germany-based Merck Generics.

Revenue rose 5 percent to $1.27 billion from $1.2 billion in the same period last year.

Excluding special items, Mylan earned 32 cents per share, in line with Wall Street estimates.

"This was yet another successful quarter on many fronts for Mylan," Chairman and CEO Robert Coury said in a statement.

Advertise with us

Based on expectations for stronger results for the second half of the year, he said Mylan was raising its full-year earnings guidance to a range of $1.13 to $1.20 per share, excluding special items, up from the previous estimated range of $1 to $1.10.

Second-quarter profits of $58.1 million included "other income" of $25.3 million, which included a favorable adjustment of $13.9 million to the company's restructuring reserve and a gain of about $10.4 million on the termination of two 50 percent-owned joint ventures, Mylan said.

During a conference call with analysts yesterday, Mr. Coury said he wanted to address a matter he termed "a short-term distraction this week."

Mylan's plant in Morgantown, W.Va., is being investigated by the Food and Drug Administration following a story in Sunday's Pittsburgh Post-Gazette citing a Mylan internal report that said workers sidestepped computer-generated warnings about potential problems with the medications they were making. Mylan's report called the quality control breach "pervasive" and "very serious." The report said no medications were compromised.

"Mylan, and especially our Morgantown, W.Va., facility, has always been recognized as the gold standard when it comes to quality," Mr. Coury told analysts.

Advertise with us

"Because we will respect the rest of the FDA's process, we will not be taking or answering any questions on this matter.

"Let me be clear, we stand by everything said in the press release that we issued Tuesday of this week," he said.

The release asserted that the FDA's probe had ended and that the agency "agreed that this was a minor standard operating procedures deviation" and that the agency "determined that the baseless accusations in the article were unfounded." The FDA also concluded that "all corrective actions were fully implemented," the release said.

Two hours after Mylan's statement Tuesday morning, FDA assistant commissioner Steven Solomon issued a statement saying the investigation at the plant was "ongoing" and that "the agency has formed no conclusions at this time. Statements to the contrary are untrue."

Yesterday, an FDA spokesman reiterated that the investigation was continuing.

Advertise with us

After the conference call, Mr. Coury fielded questions in an interview on CNBC, saying that he "did not jump the gun" when he issued his statement Tuesday. "Obviously, I would never do that," he said.

He said patients who use Mylan's drugs "needed to have some level of communication."

"I want to thank the FDA for moving so expeditiously," Mr. Coury said.

Separately, Mylan asked Morgantown employees in a memo Wednesday "to be vigilant against unauthorized disclosures of company information, inappropriate communications with outsiders or any similar misconduct."

"We need to stand together now to defend what we all know is an excellent company," the memo stated.

Advertise with us

It was signed by Mylan North America President Hal Korman, three plant managers, USW Local 8-957 President Patrick D. Fowler and other union leaders.

Mylan's stock rose 22 cents yesterday, closing at $13.13.